Carcinoid tumor
MONDO:0005369A slow growing neuroendocrine tumor, composed of uniform, round, or polygonal cells having monotonous, centrally located nuclei and small nucleoli, infrequent mitoses, and no necrosis. The tumor may show a variety of patterns, such as solid, trabecular, and acinar. Electron microscopy shows small secretory granules. Immunohistochemical studies reveal NSE, as well as chromogranin immunoreactivity. Malignant histology (cellular pleomorphism, hyperchromatic nuclei, prominent nucleoli, necrosis, and mitoses) can occasionally be seen. Such cases may have an aggressive clinical course. Gastrointestinal tract and lung are common sites of involvement.
Also known as: NET G1, carcinoid, carcinoid tumor, carcinoid tumor (disease), carcinoid tumour (disease), neuroendocrine neoplasm G1, neuroendocrine tumor G1, neuroendocrine tumour G1
1488 clinical trials for this condition and its sub-types, 33 tagged with Carcinoid tumor itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Carcinoid tumor
-
Intestinal neuroendocrine tumor G1 5 trials · 8 incl. sub-types
2 sub-types
- Small intestinal neuroendocrine tumor G1 3 trials · 5 incl. sub-types Sub-types →
- Colorectal neuroendocrine tumor G1 1 trial · 4 incl. sub-types Sub-types →
-
Somatostatinoma 6 trials
-
Pancreatic neuroendocrine tumor G1 1 trial · 5 incl. sub-types
1 sub-type
-
Atypical carcinoid tumor 4 trials
-
Gastric neuroendocrine tumor G1 2 trials
-
Lung carcinoid tumor 2 trials
-
Childhood carcinoid tumor 0 trials
Most studied deeper sub-types
-
New vaccine aims to train immune system against lung cancer
Vaccine Recruiting nowThis phase 1/2 trial is testing a vaccine made from a piece of the MUC1 protein, which is found on many lung cancer cells. The vaccine is mixed with an adjuvant called Poly-ICLC to boost the immune response. Thirty patients with early or locally advanced non-small cell lung cance…
Phase 1/2 • Sponsor: Olivera Finn • Aim: Vaccine
Last updated Jun 27, 2026 07:55 UTC
-
Radioactive drug takes aim at Hard-to-Treat tumors
Disease control Recruiting nowThis early-phase trial tests a new radioactive drug called RYZ401 in people with neuroendocrine tumors and other solid tumors that have a specific protein on their surface. The drug delivers a powerful radioactive particle directly to cancer cells. The study aims to find the safe…
Phase 1 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug combo aims to shrink Hard-to-Treat neuroendocrine tumors
Disease control Recruiting nowThis study tests whether combining Lutathera (a radioactive drug given by IV) with Olaparib (a pill) can shrink neuroendocrine tumors in the pancreas or intestine that cannot be removed by surgery. About 56 adults will receive the treatment over several cycles. The goal is to fin…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Could a simple dose change make a tough cancer drug easier to take?
Disease control Recruiting nowThis Phase II trial is testing whether a different dosing schedule of the drug cabozantinib can reduce side effects while still controlling cancer growth. It includes people with advanced kidney cancer (clear cell or non-clear cell) and neuroendocrine tumors (including carcinoid)…
Phase 2 • Sponsor: Fox Chase Cancer Center • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New radioactive drug aims to fight gut tumors that resist standard therapy
Disease control Recruiting nowThis study tests a new drug called RYZ101 in people with advanced neuroendocrine tumors (GEP-NETs) that have grown after prior radiation therapy. The trial has two parts: first finding the right dose, then comparing RYZ101 to standard treatments like everolimus or sunitinib. Abou…
Phase 3 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New pill aims to tame flushing and diarrhea in rare cancer syndrome
Symptom relief Recruiting nowThis Phase 3 trial tests whether the experimental drug paltusotine can reduce flushing and diarrhea in adults with carcinoid syndrome caused by neuroendocrine tumors. About 141 participants will receive either paltusotine or a placebo daily for 12 weeks. The study measures how mu…
Phase 3 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
Virtual reality goggles could be new tool against cancer pain
Symptom relief Recruiting nowThis study tests whether using virtual reality (VR) can reduce severe belly pain and improve quality of life in people with digestive tract cancers. 360 participants will be split into three groups: one using a skills-based VR program, one using distracting VR videos, and a contr…
Sponsor: Cedars-Sinai Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 09:07 UTC
-
Family study aims to unlock secrets of rare gut cancer
Knowledge-focused Recruiting nowThis study looks at families where multiple members have had small bowel carcinoid tumors, a rare and slow-growing cancer. Researchers want to learn how the disease develops, improve early detection, and find the genes that may cause it. Participants, including those with and wit…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
New study aims to boost safety of targeted radiation cancer treatment
Knowledge-focused Recruiting nowThis study looks at whether having a pharmacist review all medications (including those from other doctors) can improve safety for cancer patients receiving targeted radionuclide therapy. The study will include 600 adults with thyroid cancer, metastatic prostate cancer, or neuroe…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Could skipping opioids during surgery help fight colorectal cancer?
Knowledge-focused Recruiting nowThis study compares three types of anesthesia during colorectal cancer surgery: opioid-based, opioid-sparing, and opioid-free. Researchers will measure immune markers called NETs in the blood and test how the blood affects cancer cells in the lab. The goal is to see if avoiding o…
Sponsor: Fudan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Algeria launches large lung cancer registry to improve care
Knowledge-focused Recruiting nowThis study is a registry that will collect information from about 3,750 adults with lung cancer across 21 hospitals in Algeria. Researchers will track patients' health, treatments, and outcomes during routine care. The goal is to better understand lung cancer in Algeria and help …
Sponsor: Société Algérienne de Formation et de Recherche en Oncologie • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:28 UTC